Cardiovascular Medicine

5 pages, 669 KB

Open AccessReview

Current ECG Interpretation Guidelines in the Screening of Athletes

by Gemma Parry-Williams and Sanjay Sharma

Cardiovasc. Med. 2018, 21(1), 7; https://doi.org/10.4414/cvm.2018.00534 - 17 Jan 2018

Cited by 2 | Viewed by 277

Sudden cardiac death is rare, however the lives of some young athletes are lost prematurely due to cardiovascular dieseases that are detectable during life. It is on this premise that the European Society of Cardiology endorses cardiovascular screening of young athletes using the 12 lead ECG. This re-view will describe the spectrum of normal ECG patterns in athletes. the im-pact of demographic factors and sporting intensity on these patterns and de-fine the abnormal ECG findings that warrant further investigation. Full article

► Show Figures

Figure 1

4 pages, 335 KB

Open AccessEditorial

Stents Bei Angina Pectoris: Wie Wirksam Sind Sie Wirklich?

by Thomas F. Lüscher

Cardiovasc. Med. 2018, 21(1), 3; https://doi.org/10.4414/cvm.2018.00541 - 17 Jan 2018

Cited by 1 | Viewed by 49

Abstract

Vor über 200 Jahren hat William Heberden als Erster die typischen Beschwerden der Angina pectoris beschrieben und auch auf die Gefährlichkeit der Erkrankung hingewiesen (Abb. 1) [...] Full article

► Show Figures

Figure 1

7 pages, 208 KB

Open AccessCommunication

Positionspapier «Herzinsuffizienz-Curriculum» der Arbeitsgruppe Herzinsuffizienz der SGK

by Paul Mohacsi, Micha T. Maeder, Andreas J. Flammer, Philippe Meyer, Giorgio Moschovitis, Matthias Paul, Otmar Pfister, Thomas Suter, Frank Ruschitzka and Roger Hullin

Cardiovasc. Med. 2018, 21(1), 26; https://doi.org/10.4414/cvm.2018.00537 - 17 Jan 2018

Cited by 3 | Viewed by 79

Abstract

Position paper “Heart failure curriculum” by the Heart Failure Working Group of the Swiss Society of Cardiology. Cardiology has evolved dramatically within the past 2 decades due to major advances in the treatment of heart disease. At the same time, such progress has required specialization, as knowledge gains and new technological possibilities demand special focus. The European Society of Cardiology (ESC) has stayed abreast with these changes by authoring comprehensive guidelines that define an evidence-based approach not only for interventional cardiology, rhythmology, and heart failure, but also many other subfields of cardiology. Various national research groups have stated recommendations in “curricula”, defining the required specialist knowledge and technical skills fur sub-specialties. This position paper by the Heart Failure working group of the Swiss Society of Cardiology (SSC) defines the “Heart Failure” curriculum. Full article

► Show Figures

Figure 1

3 pages, 448 KB

Open AccessInteresting Images

Biphasic T Waves and Typical Chest Pain

by Julija Bianda, Fausto Bertini and Daniel Sürder

Cardiovasc. Med. 2018, 21(1), 22; https://doi.org/10.4414/cvm.2018.00536 - 17 Jan 2018

Viewed by 63

Abstract

A 69-year-old male with the history of previous colon cancer in remission and structural post-traumatic epilepsy complained of dyspnoea and epigastric pain on exertion in the previous 6 months [...] Full article

► Show Figures

Figure 1

6 pages, 192 KB

Open AccessReview

Hypercholestérolémie Familiale: Optimiser le Diagnostic et le Traitement

by David Nanchen

Cardiovasc. Med. 2018, 21(1), 16; https://doi.org/10.4414/cvm.2018.00539 - 17 Jan 2018

Viewed by 71

Abstract

Familial hypercholesterolaemia (FH) is a common genetic disorder characterised by high levels of low-density lipoprotein cholesterol (LDL-cholesterol) and early development of atherosclerosis. Recent genetic and epidemiological studies have reported the prevalence of FH in the general population and among patients with cardiovascular disease. FH remains largely underdiagnosed or diagnosed only after a first cardiovascular event, despite available simple clinical screening tools. Too often, the quality of care of patients with FH is not in line with clinical guidelines. Optimisation of lifestyle, control of all cardiovascular risk factors and maximal reduction of LDL-cholesterol levels with lipid-lowering drugs over a long period of time can greatly reduce or cancel the excess cardiovascular risk associated with FH. A new class of lipid-lowering drug, PCSK9 inhibitors, provides additional therapeutic options for patients with FH for whom optimal treatment with statins and ezetimibe cannot effectively lower their LDL-cholesterol. This review summarises the identification, diagnosis, prognosis and treatment of patients with FH. Full article

► Show Figures

Figure 1

4 pages, 285 KB

Open AccessReview

Neue Orale Antikoagulantien (NOAC) und Akuter Hirnschlag: Wie Behandeln–Ein Dilemma?

by David J. Seiffge, Gian Marco De Marchis, Christopher Tränka, Alexandros Alexandros, Leo Bonati, Nils Peters, Philippe Lyrer and Stefan T. Engelter

Cardiovasc. Med. 2018, 21(1), 12; https://doi.org/10.4414/cvm.2018.00538 - 17 Jan 2018

Viewed by 53

Abstract

What is the proper line of treatment using new oral anticoagulants (NOAC) for acute stroke? New medications from the group of thrombin inhibitors (dabigatran) and factor Xa inhibitors (apixaban, edoxaban, and rivaroxaban) have revolutionized oral anticoagulants, in the form of new and direct oral anticoagulants (NOACs and DOACs), respectively. Nonetheless, a dilemma still remains in the management of patients who have been affected by acute stroke while being administered NOACs. In accordance with current guidelines concerning effective vessel-opening acute therapy, (systemic thrombolysis or interventional treatment), these patients are excluded due to risk of intracranial haemorrhage. At the same time, it is unclear when secondary prophylaxis with NOAC can be initiated following a stroke, as patients having recently been affected by a stroke are excluded from the NOAC studies having led to approval. New data from the Basel-based NOACISP (“Novel oral anticoagulants in stroke patients”) registry and an international collaboration project between stroke centers has now made a significant contribution to resolving this question. They have managed to demonstrate that in selected patients undergoing NOAC therapy, there was no increased risk of intracranial haemorrhage with systemic thrombolysis or interventional treatment. In a secornd study, they showed thot therapy begin with an NOAC after a median 5 days following an acute stroke shows no association with increased risk of hemorrhaging. Full article

► Show Figures

Figure 1

Journal Menu

Journal Browser

Cardiovasc. Med., Volume 21, Issue 1 (01 2018) – 6 articles

Further Information

Guidelines

MDPI Initiatives

Follow MDPI